Amondys 45 (casimersen: Sarepta Therapeutics) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F
Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Amondys 45 Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.
The Amondys 45 market has experienced notable growth due to various factors, with limited treatment options and patient advocacy efforts driving early progress. Currently, advancements in gene-based therapies, exon-specific drugs, and regulatory initiatives are fueling the forecast period's expansion. Key trends include the rise of exon skipping therapies and the increased emphasis on precision genetic medicine targeting rare neuromuscular disorders.
The rising prevalence of genetic disorders is a major driver for Amondys 45's market growth. The increased availability of genetic testing enables earlier and more accurate diagnosis of conditions such as Duchenne muscular dystrophy (DMD). Amondys 45 targets specific dystrophin gene mutations, making it suitable for patients requiring exon 45 skipping. By facilitating functional dystrophin protein production, Amondys 45 aids in improving muscle function and clinical outcomes.
Additionally, growing demand for personalized medicine propels market growth. Enhanced genomic technologies are paving the way for more accurate identification of genetic variations, allowing Amondys 45 to strengthen personalized medicine. The treatment offers mutation-specific options for DMD patients whose genetic profiles are amenable to exon 45 skipping, leading to increased treatment precision. According to the Personalized Medicine Coalition, 26 new personalized medicines received FDA approval in 2023, showcasing a significant leap from 2022.
Healthcare expenditure also boosts the Amondys 45 market. Increasing financial resources for healthcare services are essential to support the growth of advanced treatments. Amondys 45 contributes to such expenditure by providing specialized treatments for DMD, while influencing market dynamics and investment opportunities. Reports from the Office for National Statistics highlighted a 5.6% rise in healthcare expenditure in the UK between 2022 and 2023.
Regionally, North America leads the Amondys 45 market, with Europe predicted as the fastest-growing region. Key global markets include Asia-Pacific, Western and Eastern Europe, North America, South America, and the Middle East and Africa, spanning countries such as the USA, UK, China, Japan, and more.
Tariffs influence the Amondys 45 market by affecting costs related to oligonucleotide synthesis materials and specialized manufacturing logistics. Despite cost pressures, tariffs encourage the localized production of rare disease therapeutics, fostering long-term access and reliability. Sarepta Therapeutics Inc. remains a major player in this market.
The Amondys 45 market report offers insights into global market size, regional shares, and competitive landscapes, featuring detailed segments and trend analyses. It outlines the prescription status of Amondys 45 (casimersen) for DMD treatment, with key indications highlighting exon 45 mutations. The market comprises sales of injectable solutions and related services, reflecting the factory gate values of these products.
Key Features:
Technologies & Future Trends
For more information about this report visit https://www.researchandmarkets.com/r/xupd9q
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.